Proactive Investors - Run By Investors For Investors

Living Cell Technologies files patent for neurological agent

The technology could reverse human brain neurodegenerative processes.
neural pathways
Identifying neuroprotective product candidates

Living Cell Technologies Ltd (ASX:LCT) has filed a provisional patent for pericyte (a type of cell) protective agents for neurological disorders including neurodegenerative and central nervous system diseases.

The invention in this provisional patent arises from Living Cell’s research collaboration with the Centre for Brain Research (CBR) at The University of Auckland.

The research collaboration explored how the company’s products can reverse human brain neurodegenerative processes associated with pericytes (and other brain cells).

Living Cell’s lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells.

After implantation, NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

The company is aiming to extend the pipeline for NTCELL by examining its effects on cell cultures derived from human brains with Alzheimer’s disease and Parkinson’s disease.

The filing of the new patent will enable Living Cell to build and extend its expertise on the efficacy of cell therapies which have the potential to treat neurodegenerative disorders.

Critically, the ability to generate data from human brain tissue cultures can potentially lead the company to identify neuroprotective product candidates.

View full LCT profile View Profile

Living Cell Technologies Ltd Timeline

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
man coughing
November 10 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use